Overview

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects the participant experiences; the goal is to improve the likelihood of killing the tumor.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Brigham and Women's Hospital
Treatments:
Cisplatin
Etoposide
Etoposide phosphate